[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360322-105":59,"doc-detail-360322-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prolonged-response-to-pembrolizumab-in-brafv600e-microsatellite-stable-metastatic-colorectal-cancer-following-an-increase-in-tumor-mutational-burden","Prolonged response to pembrolizumab in BRAFV600E - microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden","","BRAFV600E-mutant metastatic colorectal cancer remains associated with poor outcomes after chemotherapy and BRAFV600E/EGFR-targeted treatment, while immune checkpoint inhibitors show limited activity in microsatellite-stable disease. A 58-year-old woman with persistent BRAFV600E signaling and microsatellite-stable status experienced a prolonged radiological response to pembrolizumab after a dynamic increase in tumor mutational burden. Longitudinal tumor and ctDNA profiling revealed molecular evolution, including a PIK3R1 variant linked to MAPK inhibitor resistance and emergence of TMB-high features. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prolonged-response-to-pembrolizumab-in-brafv600e-microsatellite-stable-metastatic-colorectal-cancer-following-an-increase-in-tumor-mutational-burden/360322/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prolonged-response-to-pembrolizumab-in-brafv600e-microsatellite-stable-metastatic-colorectal-cancer-following-an-increase-in-tumor-mutational-burden/360322.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pembrolizumab notable in microsatellite-stable BRAFV600E-mutant metastatic colorectal cancer?","Question",{"text":112,"@type":113},"The case describes a durable response to PD-1 blockade despite microsatellite stability and prior poor outcomes with standard and targeted therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did tumor mutational burden and genomic profiling influence treatment selection?",{"text":117,"@type":113},"Longitudinal profiling showed a dynamic increase in tumor mutational burden and molecular evolution, including TMB-high status, supporting the rationale for pembrolizumab.",{"name":119,"@type":110,"acceptedAnswer":120},"What resistance-related genomic change was identified during treatment evolution?",{"text":121,"@type":113},"A PIK3R1 variant was acquired and associated with resistance to MAPK-targeted inhibition, despite persistent BRAFV600E signaling.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360322,1790340849,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Prolonged response to pembrolizumab in BRAFV600Emicrosatellite stable metastatic colorectal cancer following an increase in tumor mutational burden  \nYu-Hsuen Yang1, , Naureen Starling1, , Elizabeth Cartwright*,1  \n1 Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom  \n*Corresponding author: Elizabeth Cartwright, Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital, 203 Fulham Road, London, SW3 6JJ, UK ([Elizabeth.Cartwright@rmh.nhs.uk](Elizabeth.Cartwright@rmh.nhs.uk)) .  \nAbstract  \nBRAFV600E-mutant metastatic colorectal cancer (mCRC) is an aggressive molecular subtype associated with poor prognosis and relative chemoresistance. Outcomes following progression on chemotherapy and MAPK-targeted therapy with encorafenib plus cetuximab remain poor, highlighting an unmet need for effective later-line treatments. Immune checkpoint inhibitors have limited activity in microsatellite-stable (MSS) mCRC, and predictive biomarkers beyond mismatch repair deficiency remain poorly defined. We report a patient with BRAFV600E-mutant MSS mCRC who achieved a prolonged response to PD-1 blockade with pembrolizumab following a dynamic increase in tumor mutational burden (TMB). A 58-year-old woman initially responded to first-line chemotherapy but subsequently progressed on multiple treatment lines, including encorafenib plus cetuximab. Longitudinal genomic profiling using tumor tissue and circulating tumor DNA (ctDNA) revealed persistent BRAFV600E signaling with molecular evolution, including acquisition of a PIK3R1 variant associated with resistance to MAPK inhibition and emergence of TMB-high status. Fifth-line pembrolizumab produced a dramatic radiological response, with ongoing disease control more than 2 years later. We discuss the mechanistic framework by which a subset of BRAFV600E-mutant MSS mCRC may respond to immune checkpoint inhibition through an inflamed immune microenvironment driven by constitutive MAPK signaling. This case illustrates the interplay between tumor-agnostic biomarkers such as TMB-high and tumor-specific context, and highlights the value of longitudinal genomic profiling, including ctDNA, to identify resistance mechanisms and guide treatment selection.  \nKey words: metastatic colorectal cancer; circulating tumor DNA; immunotherapy; microsatellite stable; BRAF  \nPatient story  \nA 58-year-old woman presented in February 2020 with weight loss and post-prandial abdominal pain and underwent a right hemicolectomy for an obstructing cecal tumor. Histopathology demonstrated a poorly differentiated colon adenocarcinoma, pT3 N1c with evidence of lymphovascular invasion and circumferential resection margin involvement. The tumor was microsatellite stable (MSS) with a BRAFV600E RAS wild-type profile. Metastatic disease was confirmed on positron emission tomography computed tomography (PET-CT) with FDG-avid lymphadenopathy in the left supraclavicular fossa, para-aortic, and left gastric regions. She had no significant comorbidities, minimal alcohol intake, and no smoking history. Family history included paternal urothelial cancer and maternal ocular melanoma.  \nFrom April to June 2020, she received first-line capecitabine and oxaliplatin (CAPOX) plus bevacizumab, achieving an excellent radiological and partial metabolic response. Maintenance  \ncapecitabine plus bevacizumab continued from July 2020, with a sustained complete metabolic response for almost 2 years.  \nIn April 2022, surveillance PET-CT identified new FDG-avid mediastinal and left upper lobe abnormalities. Progression was confirmed in May 2022 via biopsy of a left supraclavicular and mediastinal lymph nodes. Tumor markers were mildly elevated (CA19-9 14 U/mL, CEA 5 U/mL) . She received 5 cycles of secondline encorafenib plus cetuximab (EC) between June and October 2022 with stable disease as best response. PET-CT in September 2022 showed a mixed metabolic response with rising C","cbCaitZtI6Jh0OE9","https://ap.wps.com/l/cbCaitZtI6Jh0OE9","pdf",1138405,"English","# Abstract\n## Patient story\n## Key points","[{\"question\":\"Why is pembrolizumab notable in microsatellite-stable BRAFV600E-mutant metastatic colorectal cancer?\",\"answer\":\"The case describes a durable response to PD-1 blockade despite microsatellite stability and prior poor outcomes with standard and targeted therapies.\"},{\"question\":\"How did tumor mutational burden and genomic profiling influence treatment selection?\",\"answer\":\"Longitudinal profiling showed a dynamic increase in tumor mutational burden and molecular evolution, including TMB-high status, supporting the rationale for pembrolizumab.\"},{\"question\":\"What resistance-related genomic change was identified during treatment evolution?\",\"answer\":\"A PIK3R1 variant was acquired and associated with resistance to MAPK-targeted inhibition, despite persistent BRAFV600E signaling.\"}]","Prolonged response to pembrolizumab in BRAFV600E - microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden | PDF",1790139605,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a930f2993754244154133964fb2f550.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/984e20e40e7e40afd7862cc474581acf.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20fbde9027f148882a75fbbed4fd6b06.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69d85bc746659cb3d95417e572e7112c.webp",980,1287]